Considerations for the design and execution of protocols for animal research and treatment to improve reproducibility and standardization: “DEPART well-prepared and ARRIVE safely”

Smith, Margaret M.; Clarke, Elizabeth C.; Little, Christopher B.

doi:10.1016/j.joca.2016.10.016

Cited by 41 publications

(43 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The problem is not simply in the reporting but in the quality and design of the study, as argued in the review by Smith et al in this issue [1]. A false negative result is as unhelpful as a false positive result and much research funding is wasted on poorly designed studies.…”

mentioning

confidence: 99%

Time to be positive about negative data?

Vincent

Malfait

2017

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

mentioning

confidence: 99%

Time to be positive about negative data?

Vincent

Malfait

2017

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

“…The ARRIVE guidelines [17] for reporting animal research are akin to the CONSORT guidelines for clinical trials, and address the frequent lack of detail in how animal experiments are reported. The DEPART guidelines [8] are an example of osteoarthritis-specific considerations for how animal experiments are designed, while all NIH-supported preclinical research must now adhere to the NIH Principles and Guidelines for Reporting Preclinical Research guidelines [18]. Applying clinical trial methods to the bench, e.g.…”

Section: Problems With Reproducing Academic Results In Industrymentioning

confidence: 99%

The Academic–Industrial Complexity: Failure to Launch

Levin

2017

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

The pharmaceutical industry has long known that approximately 80% of the results of academic laboratories cannot be reproduced when repeated in industry laboratories. Yet academic investigators are typically unaware of this problem, which severely impedes the drug development process. This “academic-industrial complication” is not one of deception, but rather a complex issue related to how scientific research is carried out and translated in strikingly different enterprises. This opinion article describes the reasons for inconsistencies between academic and industrial laboratories and what can be done to repair this failure of translation.

show abstract

“…This should entail an in-depth review of existing models and experimental procedures followed by open publication of standardized animal protocols and promotion of their use (e.g., preference setting by high profile journals and funding bodies), similar to the NEWMEDS initiative for schizophrenia research [39]. Scientists working in osteoarthritis research have recently published "considerations for the design and execution of protocols for animal research and treatment" [40] to complement the ARRIVE guidelines [35], and a guide has also been produced for Huntington's disease animal models [41]. A similar protocol could be developed and adopted for animal model research in dementia diseases.…”

Section: The Need To Improve Validation Of Potential Drug Targetsmentioning

confidence: 99%

Tackling gaps in developing life‐changing treatments for dementia

Mauricio

Benn

Davis

et al. 2019

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled “Tackling gaps in developing life-changing treatments for dementia”, hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10–15 years earlier than we currently do today.

show abstract

Considerations for the design and execution of protocols for animal research and treatment to improve reproducibility and standardization: “DEPART well-prepared and ARRIVE safely”

Abstract: Following DEPART during the design phase will enable completion of the ARRIVE checklist at the time of publication, and thus improve the quality of evidence for inclusion of experimental animal research in meta-analyses and systematic reviews: "DEPART well-prepared and ARRIVE safely".

Cited by 41 publications

References 99 publications

Time to be positive about negative data?

Time to be positive about negative data?

The Academic–Industrial Complexity: Failure to Launch

Tackling gaps in developing life‐changing treatments for dementia

Contact Info

Product

Resources

About